Home › Research › Tau biomarkers
Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers
Noh MY, Sung W, Kim H, Son B, Kim YE, Choi YY, Holtzman DM, Kim SH.. Alzheimer's & dementia (Amsterdam, Netherlands), 2026-07-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Introduction The presenilin 1 (PSEN1) p .Met233Val variant is a Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU)-eligible autosomal-dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable. Methods A 34-year-old symptomatic PSEN1 p .Met233Val carrier (APOE ε3/ε3) was prospectively followed through 26 lecanemab infusions over 12 months, with serial magnetic resonance imaging (MRI), amyloid positron emission tomography (PET), and plasma biomarkers. Results No amyloid-related imaging abnormalities occurred.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. A single 34-year-old symptomatic PSEN1 p.Met233Val carrier received 26 lecanemab infusions over 12 months with no amyloid-related imaging abnormalities, while composite Centiloid rose modestly and regional amyloid-PET changes diverged. This is one person's experience, so it cannot show whether lecanemab treats, cures, or prevents Alzheimer's disease in general.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Noh, M. Y., Sung, W., Kim, H., Son, B., Kim, Y. E., Choi, Y. Y., et al. (2026). Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.70468
Vancouver
Noh MY, Sung W, Kim H, Son B, Kim YE, Choi YY, et al. Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers. Alzheimer's & dementia (Amsterdam, Netherlands). 2026. doi:10.1002/dad2.70468. PMID: 42676462.
BibTeX
@article{noh2026-42676462,
author = {Noh, M. Y. and Sung, W. and Kim, H. and Son, B. and Kim, Y. E. and Choi, Y. Y. and Holtzman, D. M. and Kim, S. H.},
title = {{Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2026},
doi = {10.1002/dad2.70468},
pmid = {42676462},
url = {https://doi.org/10.1002/dad2.70468}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Methods A 34-year-old symptomatic PSEN1 p .Met233Val carrier (APOE ε3/ε3) was prospectively followed through 26 lecanemab infusions over 12 months, with serial magnetic resonance imaging (MRI), amyloid positron emission tomography (PET), and plasma biomarkers.
- Results No amyloid-related imaging abnormalities occurred.
- Composite Centiloid increased modestly (+7.2), masking regional divergence: basal ganglia (-24.5) and medial temporal cortex (-22.1) declined, whereas posterior cortical regions accrued amyloid.
- Plasma amyloid beta (Aβ) 42/40 rose to 122% by T22, with concurrent decreases in phosphorylated tau at threonine 217 (p-tau217), p-tau181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP).
Why it matters
A single 34-year-old symptomatic PSEN1 p.Met233Val carrier received 26 lecanemab infusions over 12 months with no amyloid-related imaging abnormalities, while composite Centiloid rose modestly and regional amyloid-PET changes diverged. This is one person's experience, so it cannot show whether lecanemab treats, cures, or prevents Alzheimer's disease in general.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 46/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | 1 / 4 | Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring: journal h-index 86 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Seung Hyun Kim: h-index 63 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42676462) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/dad2.70468
- PubMed: 42676462
- Original source →
- Free full text: Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.